Results 101 to 110 of about 12,561 (235)

Response to Oral Dapsone in a Patient With Generalised Junctional Epidermolysis Bullosa

JEADV Clinical Practice, Volume 5, Issue 2, Page 648-650, June 2026.
ABSTRACT Dapsone is a potent antibacterial agent used as a first‐line treatment for leprosy and employed also as an anti‐inflammatory agent. Additionally, dapsone is used for a variety of other cutaneous conditions. Herein, we report a case of intermediate junctional epidermolysis bullosa that improved significantly with oral 4,4’‐diamino‐diphenyl ...
Shiho Mori, Manabu Fujimoto, Katsuto Tamai   +2 more
wiley   +1 more source

Epitopes Targeted by Bullous Pemphigoid T Lymphocytes and Autoantibodies Map to the Same Sites on the Bullous Pemphigoid 180 Ectodomain

, 2000
Bullous pemphigoid is a blistering skin disease characterized by autoantibodies directed against the NC16A domain of bullous pemphigoid 180 (collagen XVII), a transmembrane protein of epidermal basal cells.
Lazaro, Ana Maria, Lin, Mong-Shang, Giudice, George J., Stastny, Peter, Olague-Marchan, Monica, Fu, Chang-Ling, Giudice, George, Diaz, Luis A., Diaz, Luis   +8 more
core   +1 more source

Bullous Pemphigoid [PDF]

Journal of General Internal Medicine, 2012
Barry, Ladizinski, Kachiu Cecelia, Lee
openaire   +2 more sources

The association between COVID‐19 vaccines and bullous pemphigoid risk: A UK population‐based study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Mikolaj Swiderski, Yana Vinogradova, Matthew J. Ridd, Zenas Z. N. Yiu, Antonia Lloyd‐Lavery, Vibhore Prasad, Bruno Gran, Sonia Gran   +7 more
wiley   +1 more source

Buccal Mucosa as Substrate for Direct Immunofluorescence Should Be Included Early in the Diagnostic Work Up of Ocular Mucous Membrane Pemphigoid

JEADV Clinical Practice, Volume 5, Issue 2, Page 597-601, June 2026.
ABSTRACT Background In ocular mucous membrane pemphigoid (MMP) direct immunofluorescence (DIF) represents the gold standard for definitive diagnosis. However, up to 50% of ocular MMP cases do not meet the immunopathological criteria. In addition, the risk of exacerbating conjunctival cicatrization makes ocular biopsy technically difficult to obtain ...
Andrea Gabusi, Michelangelo La Placa, Davide Bartolomeo Gissi, Federica Filippi, Camilla Loi, Cosimo Misciali, Federico Bardazzi   +6 more
wiley   +1 more source

Pemphigoid: Bullous and Cicatricial

Dermatologic Clinics, 1990
Bullous pemphigoid is a blistering disease of the elderly that often is self-limited. It is apparently caused by autoantibodies against antigens of the basal cell hemidesmosome. There is apparently more than one antigen, but the most significant has a molecular weight of about 230 kD and the second most frequently detected antigen has a lower molecular
openaire   +2 more sources

Granulomatous Panniculitis in a Patient Treated With Cemiplimab: Case Report and Literature Review

JEADV Clinical Practice, Volume 5, Issue 2, Page 664-668, June 2026.
ABSTRACT Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of advanced malignancies by enhancing antitumor immunity, but they may also trigger a broad spectrum of immune‐related adverse events (irAEs) involving multiple organs.
B. Lada‐Colunga, J. L. Artola‐Igarza, N. Martinez‐Peña, I. Arevalo‐Ortega, J. Rodriguez‐Blandon, G. Cancho‐Galan, R. Izu‐Belloso   +6 more
wiley   +1 more source

Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor in primary care: Case report

Turkish Journal of Family Practice
Bullous pemphigoid is the most common bullous chronic autoimmune skin disease. Recent studies suggest dipeptidyl peptidase-4 inhibitors used in the treatment of type-2 diabetes as possible predisposing agents of bullous pemphigoid.
Kübra Kurt
doaj   +1 more source

BP230‐Type Bullous Pemphigoid is a Rare Subset of Bullous Pemphigoid Associated With a Favorable Prognosis: A Retrospective Analysis From a Tertiary Referral Center

International Journal of Dermatology, Volume 65, Issue 7, Page 1460-1462, July 2026.
Roberto Maglie, Sefano Senatore, Carlo Pipitò, Maria E. Baffa, Stefano Colabrese, Sasha Visinoni, Vincenzina Rubino, Anna Pira, Feliciana Mariotti, Marzia Caproni, Giovanni Di Zenzo, Emiliano Antiga   +11 more
wiley   +1 more source

Immunotherapy‐Related Cutaneous Toxicities in Melanoma: A Dermoscopic Perspective

JEADV Clinical Practice, Volume 5, Issue 2, Page 402-414, June 2026.
Dermoscopy serves as a valuable tool in the everyday dermatological and oncological practice for melanoma patients, allowing for the prompt identification of immune‐related cutaneous toxicities and guiding clinicians toward appropriate therapeutic decisions.
Grażyna Kamińska‐Winciorek, Iris Zalaudek, Karolina Zarańska, Bożena Cybulska‐Stopa   +3 more
wiley   +1 more source